





Section: [6. Anti-infective medicines](#) > [6.4. Antiviral medicines](#) > [6.4.4. Antihepatitis medicines](#) > [6.4.4.2. Medicines for hepatitis C](#) > [6.4.4.2.1. Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations](#)

ATC codes: **J05AP07**

<b>Indication</b>	Chronic hepatitis C <span>ICD11 code: <b>1E91.1</b></span>
<b>INN</b>	Daclatasvir
<b>Medicine type</b>	Chemical agent
<b>List type</b>	Core pangenotypic when used in combination with sofosbuvir.
<b>Formulations</b>	Oral > Solid: 30 mg tablet (as hydrochloride) ; 60 mg tablet (as hydrochloride)
<b>EML status history</b>	First added in 2015 ( <a href="#">TRS 994</a> ) Changed in 2019 ( <a href="#">TRS 1021</a> )
<b>Sex</b>	All
<b>Age</b>	Adolescents and adults
<b>Therapeutic equivalence</b>	glecaprevir + pibrentasvir (ATC codes: J05AP57) sofosbuvir (ATC codes: J05AP08) sofosbuvir + velpatasvir (ATC codes: J05AP55)
<b>Patent information</b>	Main patent is active in several jurisdictions. For more information on specific patents and license status for developing countries visit <a href="http://www.MedsPal.org">www.MedsPal.org</a>  Read more <a href="#">about patents.</a> 
<b>Wikipedia</b>	<a href="#">Daclatasvir</a> 
<b>DrugBank</b>	<a href="#">Daclatasvir</a> 

## Summary of evidence and Expert Committee recommendations

The listing for daclatasvir was qualified by a note indicating that it is pangenotypic when used in combination with sofosbuvir. Pangenotypic direct acting antivirals are considered therapeutically equivalent for the purposes of selection and procurement at national level.

